(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

Civica will begin selling a type of insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...

The European Medicines Agency (EMEA) is looking into four recently published registry studies investigating a possible relationship between insulin analogues, in particular insulin glargine, and the ...

Gov. Gavin Newsom announced Thursday he is rolling out an effort to lower the price of insulin to $11. CalRx, the state-run program that aims to lower the cost of insulin and other medications, would ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...

Gov. Gavin Newsom says California will begin selling affordable insulin under its own label on Jan. 1, nearly three years ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...

HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...